{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:12:05Z","timestamp":1760137925241,"version":"build-2065373602"},"reference-count":32,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016935","name":"Lisa Dean Moseley Foundation","doi-asserted-by":"publisher","award":["unnumbered"],"award-info":[{"award-number":["unnumbered"]}],"id":[{"id":"10.13039\/100016935","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Leukemia Research Foundation of Delaware","award":["unnumbered"],"award-info":[{"award-number":["unnumbered"]}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20GM103446","P20GM103464"],"award-info":[{"award-number":["P20GM103446","P20GM103464"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016610","name":"Andrew McDonough B+ Foundation","doi-asserted-by":"publisher","award":["unnumbered"],"award-info":[{"award-number":["unnumbered"]}],"id":[{"id":"10.13039\/100016610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012465","name":"Nemours Foundation","doi-asserted-by":"publisher","award":["unnumbered"],"award-info":[{"award-number":["unnumbered"]}],"id":[{"id":"10.13039\/100012465","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Children with acute myeloid leukemia (AML) have a poor prognosis despite the intensification of chemotherapy. Future efforts to improve outcomes should focus on more precise targeting of leukemia cells. CD123, or IL3RA, is expressed on the surface of nearly all pediatric AML samples and is a high-priority target for immunotherapy. The efficacy of an investigational dual-affinity retargeting antibody (DART) molecule (CD123 \u00d7 CD3; MGD006 or flotetuzumab) was assessed in two distinct patient-derived xenograft (PDX) models of pediatric AML. MGD006 simultaneously binds to CD123 on target cells and CD3 on effector T cells, thereby activating T cells and redirecting them to induce cytotoxicity in target cells. The concurrent treatment of cytarabine and MGD006 was performed to determine the effect of cytarabine on T-cell counts and MGD006 activity. Treatment with MGD006 along with an allogeneic human T-cell infusion to act as effector cells induced durable responses in both PDX models, with CD123 positivity. This effect was sustained in mice treated with a combination of MGD006 and cytarabine in the presence of T cells. MGD006 enhanced T-cell proliferation and decreased the burden of AML blasts in the peripheral blood with or without cytarabine treatment. These data demonstrate the efficacy of MGD006 in prolonging survival in pediatric AML PDX models in the presence of effector T cells and show that the inclusion of cytarabine in the treatment regimen does not interfere with MGD006 activity.<\/jats:p>","DOI":"10.3390\/jcm11051333","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T20:11:14Z","timestamp":1646079074000},"page":"1333","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of Flotetuzumab in Combination with Cytarabine in Patient-Derived Xenograft Models of Pediatric Acute Myeloid Leukemia"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4162-3004","authenticated-orcid":false,"given":"Sonali P.","family":"Barwe","sequence":"first","affiliation":[{"name":"Nemours Centers for Childhood Cancer Research, Nemours Children\u2019s Hospital, Wilmington, DE 19803, USA"},{"name":"Nemours Center for Cancer and Blood Disorders, Nemours Children\u2019s Hospital, Wilmington, DE 19803, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Kisielewski","sequence":"additional","affiliation":[{"name":"Nemours Centers for Childhood Cancer Research, Nemours Children\u2019s Hospital, Wilmington, DE 19803, USA"},{"name":"Nemours Center for Cancer and Blood Disorders, Nemours Children\u2019s Hospital, Wilmington, DE 19803, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ezio","family":"Bonvini","sequence":"additional","affiliation":[{"name":"MacroGenics, Inc., Rockville, MD 20850, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Muth","sequence":"additional","affiliation":[{"name":"MacroGenics, Inc., Rockville, MD 20850, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Davidson-Moncada","sequence":"additional","affiliation":[{"name":"MacroGenics, Inc., Rockville, MD 20850, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward Anders","family":"Kolb","sequence":"additional","affiliation":[{"name":"Nemours Centers for Childhood Cancer Research, Nemours Children\u2019s Hospital, Wilmington, DE 19803, USA"},{"name":"Nemours Center for Cancer and Blood Disorders, Nemours Children\u2019s Hospital, Wilmington, DE 19803, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0465-578X","authenticated-orcid":false,"given":"Anilkumar","family":"Gopalakrishnapillai","sequence":"additional","affiliation":[{"name":"Nemours Centers for Childhood Cancer Research, Nemours Children\u2019s Hospital, Wilmington, DE 19803, USA"},{"name":"Nemours Center for Cancer and Blood Disorders, Nemours Children\u2019s Hospital, Wilmington, DE 19803, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Reinhardt, D., Antoniou, E., and Waack, K. (2022). Pediatric Acute Myeloid Leukemia-Past, Present, and Future. J. Clin. Med., 11.","DOI":"10.3390\/jcm11030504"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1200\/JCO.2015.62.8289","article-title":"Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia","volume":"33","author":"Zwaan","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s12185-019-02616-y","article-title":"Impact of CD123 expression, analyzed by immunohistochemistry, on clinical outcomes in patients with acute myeloid leukemia","volume":"109","author":"Arai","year":"2019","journal-title":"Int. J. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/cyto.b.21745","article-title":"CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping","volume":"96","author":"Bras","year":"2019","journal-title":"Cytom. B Clin. Cytom."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1200\/JCO.21.01595","article-title":"CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children\u2019s Oncology Group","volume":"40","author":"Lamble","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2002-03-0852","article-title":"Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis","volume":"100","author":"Testa","year":"2002","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3324\/haematol.2011.047894","article-title":"High levels of CD34+CD38low\/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: A Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study","volume":"96","author":"Vergez","year":"2011","journal-title":"Haematologica"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/bloodadvances.2019000357","article-title":"Opportunities for immunotherapy in childhood acute myeloid leukemia","volume":"3","author":"Lamble","year":"2019","journal-title":"Blood Adv."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2020.04.038","article-title":"Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration","volume":"136","author":"Pearson","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/17474086.2021.1935855","article-title":"CD123-targeted therapy in acute myeloid leukemia","volume":"14","author":"Green","year":"2021","journal-title":"Expert Rev. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Testa, U., Pelosi, E., and Castelli, G. (2019). CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies. Cancers, 11.","DOI":"10.3390\/cancers11091358"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","article-title":"The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells","volume":"14","author":"Jordan","year":"2000","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.stem.2009.04.018","article-title":"Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells","volume":"5","author":"Jin","year":"2009","journal-title":"Cell Stem Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"289ra282","DOI":"10.1126\/scitranslmed.aaa5693","article-title":"A CD3 \u00d7 CD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates","volume":"7","author":"Chichili","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/blood-2014-05-575704","article-title":"Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform","volume":"127","author":"Rettig","year":"2016","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2021-153192","article-title":"Combinatorial Anti-Tumor Activity in Animal Models of a Novel CD123 \u00d7 CD3 Bispecific Dart\u00ae Molecule (MGD024) with Cytarabine, Venetoclax or Azacitidine Supports Combination Therapy in Acute Myeloid Leukemia","volume":"138","author":"Alderson","year":"2021","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1182\/blood-2019-126791","article-title":"Effect of Ara-C on T-Cell Function and Flotetuzumab Activity in Pediatric Acute Myeloid Leukemia","volume":"134","author":"Gopalakrishnapillai","year":"2019","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3389\/fonc.2016.00162","article-title":"Generation of Pediatric Leukemia Xenograft Models in NSG-B2m Mice: Comparison with NOD\/SCID Mice","volume":"6","author":"Gopalakrishnapillai","year":"2016","journal-title":"Front. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.5808\/GI.2020.18.1.e6","article-title":"Strong concordance between RNA structural and single nucleotide variants identified via next generation sequencing techniques in primary pediatric leukemia and patient-derived xenograft samples","volume":"18","author":"Barwe","year":"2020","journal-title":"Genom. Inform."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ccell.2016.03.008","article-title":"The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice","volume":"29","author":"Townsend","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3324\/haematol.2014.113092","article-title":"Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice","volume":"100","author":"Lee","year":"2015","journal-title":"Haematologica"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/(SICI)1097-0320(19981001)33:2<206::AID-CYTO15>3.0.CO;2-Y","article-title":"Quantitation of CD38 expression using QuantiBRITE beads","volume":"33","author":"Iyer","year":"1998","journal-title":"Cytometry"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2006-09-047399","article-title":"CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy","volume":"109","author":"Walter","year":"2007","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","article-title":"Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells","volume":"123","author":"Gill","year":"2014","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/leu.2014.62","article-title":"Chimeric antigen receptors against CD33\/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo","volume":"28","author":"Pizzitola","year":"2014","journal-title":"Leukemia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/bjh.12282","article-title":"Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor","volume":"161","author":"Tettamanti","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/bloodadvances.2018017517","article-title":"A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells","volume":"2","author":"Kovtun","year":"2018","journal-title":"Blood Adv."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/cei.12060","article-title":"The effects of chemotherapeutic drugs on human monocyte-derived dendritic cell differentiation and antigen presentation","volume":"172","author":"Hu","year":"2013","journal-title":"Clin. Exp. Immunol."},{"key":"ref_31","first-page":"3022","article-title":"Immunological effects of a low-dose cytarabine, aclarubicin and granulocyte-colony stimulating factor priming regimen on a mouse leukemia model","volume":"16","author":"Chen","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13045-015-0205-6","article-title":"Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 x anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells","volume":"8","author":"Fan","year":"2015","journal-title":"J. Hematol. Oncol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/5\/1333\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:29:09Z","timestamp":1760135349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/5\/1333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,28]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["jcm11051333"],"URL":"https:\/\/doi.org\/10.3390\/jcm11051333","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2022,2,28]]}}}